We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Agilent Technologies | NYSE:A | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 1.93 | 1.40% | 139.45 | 140.95 | 138.41 | 139.69 | 1,097,924 | 01:00:00 |
From May 2019 to May 2024
By Colin Kellaher
Agilent Technologies Inc. (A) said it agreed to buy ACEA Biosciences Inc., a developer of cell-analysis instruments for life-science research and clinical diagnostics, for $250 million in cash.
Agilent, a Santa Clara, Calif., provider of application-focused solutions to the life-sciences, diagnostics and applied-chemical markets, said the deal adds a differentiated portfolio and capabilities in the fast-growing cell-analysis market.
ACEA, based in San Diego, has a large manufacturing and research-and-development footprint in Hangzhou, China, Agilent said.
Agilent entered the cell-analysis market in 2015 with its $235 million purchase of Seahorse Bioscience. The company in January expanded its cell-analysis portfolio by acquiring Luxcel Biosciences.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 26, 2018 06:57 ET (10:57 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Agilent Technologies Chart |
1 Month Agilent Technologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
